Literature DB >> 33650786

Rosiglitazone promotes glucose metabolism of GIFT tilapia based on the PI3K/Akt signaling pathway.

Dong-Yan Guan1, Hui-Wen Sun1, Ji-Ting Wang1, Zhen Wang1, Yang Li1, Hao-Jun Han1, Xiang Li1, Ting-Ting Fang1.   

Abstract

The study aimed to explore the effects of rosiglitazone on glucose metabolism of GIFT tilapia based on the PI3K/Akt signaling pathway. The experiment was divided into five groups: normal starch group (32%, LC), high starch group (53%, HC), high starch +rosiglitazone group 1 (10 mg/kg, R1), high starch + rosiglitazone group 2 (20 mg/kg, R2), and high starch + rosiglitazone group 3 (30 mg/kg, R3). The results showed that a high starch diet supplemented with 10-20 mg/kg rosiglitazone had a better specific growth rate and protein efficiency that was beneficial for the growth of the tilapia. Rosiglitazone had no significant effect on the contents of crude lipid, crude protein, crude ash, and moisture of the whole fish body (p > 0.05). The contents of triglycerides and total cholesterol in the R1, R2, and R3 groups were lower than those in the HC group. The levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) in R1 and R2 groups were significantly lower than those in the HC groups (p < 0.05). However, the GOT and GPT levels in the R3 groups were significantly higher than those in the R1 and R2 groups (p < 0.05). With an increase in the rosiglitazone concentration, the contents of serum glucose, insulin, and hepatic glycogen in the R1, R2, and R3 groups decreased gradually. Meanwhile, the muscle glycogen content in the R1, R2, and R3 groups increased gradually. The mRNA expression of the IRS-1, PI3K, GLUT-4, and Akt proteins in the R1, R2, and R3 groups was significantly higher than that in the HC group (p < 0.05). Compared with the HC group, the expression of the GSK-3 mRNA in the R1, R2, and R3 groups was significantly reduced (p < 0.05). The protein expression of p-Akt in the R1 and R2 groups was higher than that in the HC group (p > 0.05). The protein expression of p-GSK-3β in the R1 and R2 groups was significantly higher than that in the HC group (p < 0.05). In conclusion, a high starch diet supplemented with rosiglitazone can improve growth, enhance the serum biochemical indices, and increase the muscle glycogen content in the GIFT tilapia. It benefits in upregulating the IRS-1, PI3K, and GLUT-4 mRNA levels in the skeletal muscle and promotes glucose uptake. Meanwhile, the phosphorylation of Akt and GSK-3β increased significantly and resulted in the inactivation of GSK-3β and alleviation of insulin resistance.
© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Entities:  

Keywords:  GIFT tilapia; PI3K/Akt; glucose metabolism; growth; rosiglitazone

Mesh:

Substances:

Year:  2021        PMID: 33650786      PMCID: PMC7923568          DOI: 10.14814/phy2.14765

Source DB:  PubMed          Journal:  Physiol Rep        ISSN: 2051-817X


  28 in total

1.  IGF-I and insulin receptor signal transduction in trout muscle cells.

Authors:  Juan Castillo; Ina Ammendrup-Johnsen; Marta Codina; Isabel Navarro; Joaquim Gutiérrez
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-01-26       Impact factor: 3.619

2.  The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naïve patients with type 2 diabetes.

Authors:  M Ahluwalia; M Evans; K Morris; C Currie; S Davies; A Rees; A Thomas
Journal:  Diabetes Obes Metab       Date:  2002-11       Impact factor: 6.577

3.  Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth.

Authors:  J L Liu; S Yakar; D LeRoith
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

Review 4.  PDK1, one of the missing links in insulin signal transduction?

Authors:  P Cohen; D R Alessi; D A Cross
Journal:  FEBS Lett       Date:  1997-06-23       Impact factor: 4.124

5.  Reference blood chemical values in ostriches (Struthio camelus).

Authors:  A Levy; B Perelman; T Waner; M van Grevenbroek; C van Creveld; R Yagil
Journal:  Am J Vet Res       Date:  1989-09       Impact factor: 1.156

Review 6.  Glitazones: clinical effects and molecular mechanisms.

Authors:  Michael Stumvoll; Hans-Ulrich Häring
Journal:  Ann Med       Date:  2002       Impact factor: 4.709

7.  Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.

Authors:  Arjunan Sundaresan; Thangaiyan Radhiga; Kodukkur Viswanathan Pugalendi
Journal:  J Physiol Biochem       Date:  2016-04-18       Impact factor: 4.158

8.  Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways.

Authors:  Joe-Lin du Toit-Kohn; Louise Louw; Anna-Mart Engelbrecht
Journal:  J Nutr Biochem       Date:  2008-05-13       Impact factor: 6.048

9.  Inhibition of perivascular mast cell activation is involved in the atheroprotective effect of rosiglitazone in apolipoprotein E-deficient mice.

Authors:  Qinglang Li; Ying Xiao; Guihua Lu; Dongmei Xie; Yuansheng Zhai; Juhong Zhang; Jie Li; Xiuren Gao
Journal:  Biochem Biophys Res Commun       Date:  2019-09-05       Impact factor: 3.575

10.  Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression.

Authors:  Hyo-Sup Kim; Jung-Hyun Noh; Seung-Hyun Hong; You-Cheol Hwang; Tae-Young Yang; Myung-Shik Lee; Kwang-Won Kim; Moon-Kyu Lee
Journal:  Biochem Biophys Res Commun       Date:  2008-01-11       Impact factor: 3.575

View more
  1 in total

1.  Tertiary butylhydroquinone alleviated liver steatosis and increased cell survival via β-arrestin-2/PI3K/AKT pathway.

Authors:  Tian-Tian Zhu; Chao-Nan Zhu; Yue Qiu; Qian-Shuai Li; Xin Yu; Guo-Jie Hao; Ping Song; Jian Xu; Peng Li; Ya-Ling Yin
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.